Cambridge UK's PhoreMost, a biotech that specializes in novel ligase discovery for protein degradation and molecular glues, topped up its series B to over $50M this month

Sep 24, 2024
1 min read

CEO Neil Torbett describes the SITESEEKER target ID platform that is the company's foundation. More color on individual programs will be disclosed at the upcoming Targeted Protein Degradation & Induced Proximity Symposium in October.

https://vimeo.com/1012453772

Recent Posts

See All

Artiva's cell therapy approach to autoimmune conditions is unique because it is NK cell based, donor derived, and there is no engineering of the cells - they believe the benefit is already in the data

BIO 2026: AltruBio believes that its PSGL-1, a T-cell checkpoint targeting antibody, could be a "ceiling raiser" in the I&I space

BIO 2026: Kivu Bioscience exited stealth late last year to develop "kinder and gentler" antibody-drug conjugates with a lower antibody to payload ratio to improve precision and tolerability

Cambridge UK's PhoreMost, a biotech that specializes in novel ligase discovery for protein degradation and molecular glues, topped up its series B to over $50M this month

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight